Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung CancerBiagio Ricciuti, Mark M. Awad, Giuseppe Lamberti et al.|Journal of Clinical Oncology|2024Cited by 124
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancerGiacomo Oliveira, Ravindra Uppaluri, Ann Marie Egloff et al.|Science Immunology|2023Cited by 118
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S. Garcia, Robert J. Soiffer, Eric S. Winer et al.|Blood|2022Cited by 51
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid diseaseLivius Penter, Catherine J. Wu, Yang Liu et al.|Blood|2023Cited by 51
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid CarcinomaKartik Sehgal, Jochen H. Lorch, Θεοδώρα Παππά et al.|JAMA Oncology|2024Cited by 38